Evaluation of ICL670, a Once‐Daily Oral Iron Chelator in a Phase III Clinical Trial of β‐Thalassemia Patients with Transfusional Iron Overload | Zendy

GALANELLO RENZO | Zendy

Premium

Evaluation of ICL670, a Once‐Daily Oral Iron Chelator in a Phase III Clinical Trial of β‐Thalassemia Patients with Transfusional Iron Overload

Author(s) -

GALANELLO RENZO

Publication year - 2005

Publication title -

annals of the new york academy of sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.712

H-Index - 248

eISSN - 1749-6632

pISSN - 0077-8923

DOI - 10.1196/annals.1345.021

Subject(s) - medicine , osteoporosis , osteopenia , thalassemia , calcitonin , endocrinology , diabetes mellitus , gastroenterology , vitamin d and neurology , bone mineral

A bstract : Osteoporosis and osteopenia are frequent complications of thalassemia major (TM) and intermedia (TI). Osteoporosis was found in 23/25 patients with TI and in 115/239 patients with TM. In TM, no association was found with specific polymorphisms in candidate genes (vitamin D receptor, estrogen receptor, calcitonin receptor, and collagen type 1 alpha 1). Osteoporosis in TM female was strongly associated with primary amenorrhea (P < .0001), while in male patients with TM hypogonadism was not significantly related to BMD ( P = .0001 ). Low BMD was also associated with cardiomiopathy ( P = .01 ), diabetes mellitus ( P = .0001 ), chronic hepatitis ( P = .0029 ), and increased ALT ( P = .01 ).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research